AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04219462 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active extracorporeal shock wave
Description: Ultrasound gel was used as a coupling agent, and the applicator of extracorpral shock wave therapy (ESWT) will be held perpendicular to the treatment surface throughout the treatment. Men in this group (n= 20) men receive ESWT twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura + 5 mg sildnafil once daily for 3 months
Study NCT04219462 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham extracorporeal shock wave
Description: twenty men will receive sham treatment underwent identical therapy with ESWT application with a similar appearance and sound as the active extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
Study NCT02721979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT02721979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02721979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02721979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02347696 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
Study NCT02347696 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LGIMD
Description: Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
Study NCT02347696 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Endurance Activity (EA)
Description: Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity:~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1.
Study NCT02347696 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EA+Resistance Training (RT)
Description: Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity (for Endurance activity):~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1.~Resistance activity:~Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);~* Progression: increase of 1-2.5 kg\*week-1~* Training of all muscle groups in the same session
Study NCT02347696 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LGIMD+EA
Description: Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
Study NCT02347696 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LGIMD+EA/RT
Description: Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
Study NCT02902679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Study NCT01440790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose bolus
Description: 50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
Study NCT01440790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose sipping
Description: 50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
Study NCT01600963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Failure During Double-blind Phase: TMC207
Description: Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
Study NCT01600963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment Failure During Double-blind Phase: TMC207
Description: Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
Study NCT01600963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Failure During Follow-up Phase: TMC207
Description: Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
Study NCT01600963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment Failure During Follow-up Phase: TMC207
Description: Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
Study NCT03018925 — intervention group
Intervention type: DRUG
Intervention: Golimumab
Description: The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.
Study NCT01440790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose bolus plus 1g vitamin C
Description: 50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
Study NCT01440790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose sipping plus 1g vitamin C
Description: 50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
Study NCT01726660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT Robotic Arm therapy
Description: Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
Study NCT01282476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat with Rituximab
Description: Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m\^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
Study NCT01783093 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Collection of data from existing medical records
Study NCT01564082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETT First (GlideScope)
Description: Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
Study NCT05924490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time strategy-based videogame training
Description: Rise of Nation is a complex strategy-based video game, in which individualized-adaptive feedbacks are constantly given to players based on their performance.
Study NCT05924490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semantic Knowledge training
Description: Packages of various cross-word puzzles include word search, word ladder, and word wheel.
Study NCT02209636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Description: Non-calcium containing phosphorus binder
Study NCT01554202 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ApoE4
Study NCT00655356 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face.
Study NCT01446510 — intervention group
Intervention type: OTHER
Intervention: Application of VTE Risk Assessment
Description: Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
Study NCT02225782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
Study NCT02225782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
Study NCT00087529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study NCT00087529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study NCT04129333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The hypnosis session :~* Creation of the therapist-patient link~* Choice of a theme and the preferred sensory channel by the patient~* Collection of the theme chosen by the patient~* Orientation in the here and now.~* Induction~* Realization of the gesture and hypnosis~* At the end of the procedure, reassociation of the patient in the here and now
Study NCT04129333 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No hypnosis
Description: No hypnosis
Study NCT04047927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiFinder
Description: The EpiFinder is a sensing device intended to assist physicians performing placement of epidural needle analgesic and/or anesthesia injection in a safely and accurately manner. The device is a single use sterile device consisting of a probe (Stylet), an actuator (micro DC motor), IR sensor and Controller. The device is integrated to a standard LOR Syringe and an 18G Tuohy needle and enables to simultaneously work with the standard LOR technique.
Study NCT01554202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations
Study NCT02231047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 64N Nutraceutical
Description: 40 mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days)
Study NCT02231047 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No 64N Nutraceutical
Description: 12 ounce warm drink daily for 1 week (7 days)
Study NCT03109847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given Orally
Study NCT03109847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radioactive Iodine
Description: Undergo radioactive iodine treatment
Study NCT03109847 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radioactive Iodine
Description: Undergo radioactive iodine treatment
Study NCT03109847 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT03239561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-1020
Description: Participants will receive a single intravenous bolus injection of \[18F\]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
Study NCT04146532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 500 MG
Description: Single 500mg aspirin capsule.
Study NCT04146532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single 500mg placebo capsule.
Study NCT01498510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT for chronic pain
Description: An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that is designed to train chronic pain patients in self-management skills to reduce pain and aberrant behavior and improve functioning
Study NCT02165852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Papillectomy without injection
Description: Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
Study NCT02165852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Papillectomy with injection
Description: Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
Study NCT04243369 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-diagnostic software solution
Description: Collaboration Live is a non-diagnostic software solution intended for use with Philips (Philips Ultrasound, 22100 Bothell Everett Highway, Bothell, Washington 98021) EPIQ and Affiniti Series Ultrasound Systems (software version 5.0.2) that allows users to communicate (by text, voice, screen share, webcam video and remote takeover) from an ultrasound system or workstation to a remote destination.
Study NCT00534846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toremifene
Description: The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
Study NCT00534846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
Study NCT04084639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mycoprotein Ingestion
Description: Ingestion of various doses of mycoprotein compared to placebo control
Study NCT03321812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: decalcification bone scaffold
Description: Decalcification bone scaffold is a tissue engineering acellular matrix scaffold with the closest biomechanics and structure of normal cartilage.
Study NCT03321812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microfracture
Description: Microfracture is the surgical option for conventional treatment of cartilage defects.
Study NCT03321812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microfracture
Description: Microfracture is the surgical option for conventional treatment of cartilage defects.
Study NCT01300143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)
Study NCT01300143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TACE+ RTC
Description: Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
Study NCT02734732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim/Sulfamethoxazole
Study NCT02734732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Study NCT02734550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
Study NCT02734550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
Study NCT02734550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (1,3)-β-D-glucan guided therapy
Description: Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
Study NCT03178461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body temperature parenteral fluids
Description: 2 study groups shall receive the same parenteral fluids but at different temperatures.
Study NCT00108810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Ketoprofen Patch with CHADD
Description: 12 hours patch application for 28 days
Study NCT00108810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch
Description: 12 hours application for 28 days
Study NCT01396525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnilink Elite™ Peripheral Balloon-Expandable Stent System
Description: Patients with treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
Study NCT01398254 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary Percutaneous Coronary Intervention (PPCI)
Description: Participants will be randomly assigned an access site, radial or femoral, for PPCI.
Study NCT02642861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine
Description: cyclobenzaprine administration for 2 weeks
Study NCT02642861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate for 2 weeks
Study NCT01787591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-Free Milk
Description: Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
Study NCT01787591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Fat Milk
Description: Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
Study NCT01787591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full-Fat Milk
Description: Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
Study NCT01787591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Milk
Description: Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
Study NCT02282332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study NCT04601272 — intervention group
Intervention type: BEHAVIORAL
Intervention: Decision aid
Description: Healthwise patient decision aids for breast, prostate, colon and lung cancer screening provide information on the pros and cons of cancer screening and guidance in process of selecting a choice.
Study NCT03320148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led primary care model for back pain
Description: 1. Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination~2. Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~3. Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~4. Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans.
Study NCT03320148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
Study NCT00172380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Plus CDDP
Description: docetaxel 36mg/m2 and cisplatin 75mg/m2
Study NCT02278146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ParaPatch
Description: A device for the treatment of urinary incontinence
Study NCT03513380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: free access to the exergame PedalTanks during 6 months
Study NCT03935646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall IR 10mg
Description: At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.
Study NCT03935646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02042131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Study NCT04467996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine balloon tamponade
Description: Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.
Study NCT04084639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mycoprotein Ingestion
Description: Ingestion of various doses of mycoprotein compared to placebo control
Study NCT02587663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo bilateral breast contrast enhanced MRI
Study NCT02587663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mammography
Description: Undergo bilateral mammography
Study NCT02587663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Undergo bilateral mammography
Study NCT02587663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo breast conserving surgery